Zenas BioPharma, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses; June 16, 2025 Deadline to file Lead Plaintiff Motion

Core Viewpoint - Zenas BioPharma is facing a class action lawsuit due to allegations of misleading information in its IPO registration statement, which has resulted in significant financial losses for investors [1][3][4]. Group 1: Company Overview - Zenas BioPharma is a clinical-stage biopharmaceutical company focused on developing and commercializing immunology-based therapies [3]. Group 2: IPO Details - The company sold over 13 million shares at a price of $17.00 each during its IPO [3]. - The IPO registration statement claimed that Zenas BioPharma could fund its operations for 24 months using existing cash and anticipated IPO proceeds [3]. Group 3: Allegations and Financial Impact - The class action lawsuit alleges that the IPO documents were materially false and misleading, particularly regarding the funding timeline [3]. - On November 12, 2024, Zenas BioPharma disclosed in its quarterly report that it could only fund operations for 12 months, contradicting the earlier statement [4]. - As of April 15, 2025, the stock price had dropped to $8.72, representing a decline of 48.7% from the IPO price [4].